Canagliflozin: A Comprehensive Monograph on a Foundational SGLT2 Inhibitor from Glycemic Control to Cardiorenal Protection

Abstract

Canagliflozin is a small molecule drug belonging to the sodium-glucose co-transporter 2 (SGLT2) inhibitor class, representing a significant advancement in the management of type 2 diabetes mellitus (T2DM) and related cardiorenal complications. As the first SGLT2 inhibitor approved in the United States, its primary mechanism of action involves the inhibition of glucose reabsorption in the proximal renal tubules, leading to increased urinary glucose excretion and a subsequent reduction in plasma glucose levels, independent of insulin pathways. Initially indicated as an adjunct to diet and exercise for glycemic control, the therapeutic role of canagliflozin has been profoundly expanded by the findings of landmark clinical trials. The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program demonstrated its efficacy in reducing the risk of major adverse cardiovascular events (MACE) in patients with T2DM and high cardiovascular risk. Subsequently, the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial established its potent renoprotective effects, showing a significant reduction in the progression of diabetic kidney disease. More recent evidence from trials like CHIEF-HF suggests emerging benefits in improving symptoms of heart failure, even in patients without diabetes. This comprehensive monograph details the chemical profile, pharmacology, pharmacokinetics, and extensive clinical evidence supporting canagliflozin's efficacy across its approved indications. It provides a thorough analysis of its safety and tolerability profile, including notable risks such as genital mycotic infections, diabetic ketoacidosis, and a historically important concern regarding lower limb amputations, which has since been contextualized by further data. Dosing guidelines, drug interactions, and a comparative analysis within the SGLT2 inhibitor class are also presented, positioning canagliflozin as a foundational agent in the integrated management of cardiorenal-metabolic disease.

1.0 Introduction: The Evolution of a Therapeutic Agent

The management of type 2 diabetes mellitus (T2DM) has undergone a paradigm shift over the past decade, moving from a purely glucose-centric approach to a more holistic strategy focused on mitigating cardiovascular and renal risk. Central to this evolution has been the emergence of the sodium-glucose co-transporter 2 (SGLT2) inhibitor class of medications.[1]

1.1 Overview of the SGLT2 Inhibitor Class

The kidneys have emerged as a pivotal therapeutic target in diabetes management.[1] The SGLT2 protein, expressed predominantly in the S1 segment of the proximal convoluted tubule, is responsible for reabsorbing approximately 90% of the glucose filtered by the renal glomeruli.[3] SGLT2 inhibitors, also known as gliflozins, act by selectively blocking this transporter. This action prevents the reuptake of glucose from the glomerular filtrate back into the bloodstream, thereby promoting urinary glucose excretion (glucosuria) and lowering blood glucose levels.[2]

A key feature of this drug class is its insulin-independent mechanism of action. Unlike many traditional antidiabetic agents that rely on beta-cell function or insulin sensitivity, SGLT2 inhibitors offer efficacy across different stages of T2DM.[1] This unique mechanism also confers a low intrinsic risk of hypoglycemia when used as monotherapy.[1] Beyond glycemic control, the class is associated with modest but clinically meaningful benefits, including reductions in body weight, attributed to the daily loss of 200 to 400 kilocalories via glucosuria, and reductions in both systolic and diastolic blood pressure, largely due to an osmotic diuretic effect.[1]

1.2 Development and Regulatory History of Canagliflozin

Canagliflozin was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen Pharmaceuticals, a division of Johnson & Johnson.[3] On March 29, 2013, it achieved a milestone by becoming the first SGLT2 inhibitor to receive approval from the U.S. Food and Drug Administration (FDA), marketed under the brand name Invokana.[3]

The regulatory and clinical journey of canagliflozin mirrors the transformative story of the entire SGLT2 inhibitor class. Its initial approval was as an adjunct to diet and exercise to improve glycemic control in adults with T2DM.[9] At the time, new antidiabetic agents were required by the FDA to undergo cardiovascular outcome trials (CVOTs) to demonstrate cardiovascular safety. The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program was initiated to fulfill this post-marketing requirement.[11] The results of this program were paradigm-shifting; not only did canagliflozin prove to be safe, but it demonstrated significant efficacy in reducing major adverse cardiovascular events (MACE).[12] This unexpected finding initiated the transition of SGLT2 inhibitors from being considered simply as glucose-lowering drugs to agents with profound cardiorenal protective effects.

This evolution was further solidified by the CREDENCE trial, which was specifically designed to evaluate renal outcomes and was stopped early due to overwhelming evidence of benefit in patients with diabetic kidney disease.[14] These landmark trials led to significant expansions of canagliflozin's approved indications to include the reduction of MACE risk in patients with T2DM and established cardiovascular disease, and the reduction of end-stage kidney disease (ESKD) risk in patients with T2DM and diabetic nephropathy.[10] This trajectory has fundamentally altered clinical practice guidelines, positioning canagliflozin and its class as cornerstone therapies in the comprehensive management of cardiorenal-metabolic disease.

2.0 Chemical Profile and Pharmacology

Canagliflozin is a well-characterized small molecule with distinct physicochemical properties and a novel pharmacological mechanism that has redefined treatment paradigms.

Table 1: Drug Identification and Chemical Properties

Property	Detail	Source(s)
Generic Name	Canagliflozin	16
DrugBank ID	DB08907	16
Type	Small Molecule	16
CAS Number	842133-18-0 (free base); 928672-86-0 (hemihydrate)	3
Brand Names	Invokana, Invokamet, Invokamet XR, Vokanamet, Sulisent, Prominad	16
Chemical Formula	C24​H25​FO5​S	3
Molecular Weight	444.52 g/mol	3
IUPAC Name	(3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol	3
SMILES	[H][C@]1(OC@H[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1
InChI Key	XTNGUQKDFGDXSJ-KKEQRHKBSA-N
Synonyms	JNJ-28431754, TA-7284

2.1 Physicochemical Properties and Formulation

Canagliflozin is an oral C-glycosyl compound, a structural feature that confers resistance to gastrointestinal degradation by beta-glucosidases. Its chemical structure includes a distinctive thiophene ring. It is commercially available for oral administration as film-coated tablets in strengths of 100 mg and 300 mg, based on the anhydrous weight of the active ingredient. Furthermore, it is formulated in fixed-dose combinations with both immediate-release and extended-release metformin, marketed as Invokamet and Invokamet XR, respectively, to simplify treatment regimens for patients requiring combination therapy.

2.2 Mechanism of Action

The primary therapeutic effect of canagliflozin is derived from its potent and selective inhibition of the SGLT2 protein located in the proximal renal tubules. By blocking SGLT2, which is responsible for the reabsorption of approximately 90% of filtered glucose, canagliflozin effectively lowers the renal threshold for glucose (RTG)—the plasma glucose concentration above which glucose appears in the urine. This leads to a dose-dependent increase in urinary glucose excretion (UGE), thereby reducing hyperglycemia.

Canagliflozin exhibits high selectivity for SGLT2 over the related SGLT1 transporter. In vitro studies using Chinese Hamster Ovary (CHO) cells have determined the half-maximal inhibitory concentration (IC50​) for human SGLT2 (hSGLT2) to be approximately 4.4 nM. In contrast, its inhibition of SGLT1 is substantially less potent, with reported

IC50​ values for human SGLT1 (hSGLT1) in the range of 684 nM to 910 nM. This selectivity profile ensures that the primary pharmacological effect is targeted to the kidneys.

However, the weaker but present inhibition of SGLT1 may contribute to its overall clinical profile. SGLT1 transporters are highly expressed in the lumen of the small intestine, where they mediate the absorption of glucose and galactose. By partially inhibiting intestinal SGLT1, canagliflozin can delay glucose absorption from the gut. This dual action may contribute to a more pronounced reduction in postprandial glucose excursions, which provides a pharmacological rationale for the clinical recommendation to administer the drug before the first meal of the day to maximize this effect.

2.3 Pharmacodynamics

The pharmacodynamic effects of canagliflozin are a direct extension of its mechanism of action. It produces a dose-dependent reduction in the calculated RTG and a corresponding increase in UGE. This glucose-lowering effect is independent of insulin secretion or action, which allows canagliflozin to be effective in patients with varying degrees of beta-cell dysfunction and insulin resistance, characteristic of the progression of T2DM.

Beyond its effects on glucose homeostasis, canagliflozin has demonstrated other pharmacodynamic activities. In vitro studies have shown that it can directly activate AMP-activated protein kinase (AMPK), a central regulator of cellular energy metabolism, in both liver (HepG2) and intestinal (Caco2) cell lines. This AMPK activation was found to be a necessary step for the upregulation of ATP-binding cassette transporters G5 and G8 (Abcg5/Abcg8), which are involved in cholesterol efflux. While the direct clinical translation of this finding requires further investigation, it points to pleiotropic effects that may contribute to the broader metabolic benefits observed with the drug.

2.4 Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of canagliflozin supports a once-daily dosing regimen.

• Absorption: Following oral administration, canagliflozin is well absorbed, with a mean absolute oral bioavailability of approximately 65%. Peak plasma concentrations (Cmax​) are typically achieved within 1 to 2 hours. While administration with a high-fat meal does not alter its bioavailability (AUC), it can delay the time to reach peak concentration (Tmax​).
• Distribution: Canagliflozin is extensively distributed into tissues, with a steady-state volume of distribution (Vd​) of 83.5 L in healthy individuals following a single intravenous infusion. It is highly bound to plasma proteins (99%), predominantly albumin, which limits its glomerular filtration.
• Metabolism: The primary route of metabolism for canagliflozin is O-glucuronidation, a phase II metabolic reaction. This process is mediated mainly by the uridine diphosphate-glucuronosyltransferase (UGT) enzymes UGT1A9 and UGT2B4, which convert canagliflozin into two inactive O-glucuronide metabolites, M5 and M7. Metabolism via the hepatic cytochrome P450 (CYP) system, specifically CYP3A4, is a minor pathway, accounting for only about 7% of its clearance in humans. This metabolic profile is clinically significant, as it reduces the potential for many common drug-drug interactions involving the CYP enzyme system. However, it also creates a susceptibility to drugs that are potent inducers of UGT enzymes. Co-administration with a UGT inducer, such as rifampin, can accelerate the metabolism of canagliflozin, leading to reduced plasma concentrations and potentially diminished efficacy. This direct pharmacological interaction underpins the clinical guideline to increase the canagliflozin dosage when used concomitantly with such agents.
• Excretion: The elimination half-life (t1/2​) of canagliflozin is approximately 10 to 13 hours, supporting once-daily dosing. Consistent with its primary metabolic clearance, renal clearance of the parent drug is very low, ranging from 1.30 to 1.55 mL/min.

3.0 Clinical Efficacy in Type 2 Diabetes Mellitus

Canagliflozin has demonstrated robust efficacy in improving glycemic control and other metabolic parameters in a broad range of patients with T2DM, as evidenced by a comprehensive clinical trial program.

3.1 Monotherapy and Combination Therapy for Glycemic Control

Canagliflozin has proven effective both as a monotherapy for patients inadequately controlled with diet and exercise and as an add-on therapy to a variety of other antidiabetic agents. Clinical studies have consistently shown that canagliflozin, at doses of 100 mg and 300 mg once daily, produces statistically significant reductions in glycosylated hemoglobin (

HbA1c​), fasting plasma glucose (FPG), and 2-hour postprandial glucose levels when compared with placebo.

When used in combination therapy, canagliflozin enhances glycemic control beyond that achieved with existing treatments. It has been studied as an add-on to metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, and insulin. In a head-to-head comparative trial, canagliflozin was found to be noninferior to the DPP-4 inhibitor sitagliptin, with subsequent analyses demonstrating its superiority in reducing

HbA1c​. Furthermore, in an 18-week, placebo-controlled trial involving patients with inadequate glycemic control on insulin, the addition of canagliflozin (100 mg or 300 mg) resulted in significant improvements in

HbA1c​ and FPG. In that study, 20-25% of patients receiving canagliflozin achieved an HbA1c​ target of less than 7%, compared with only 8% of patients receiving placebo as an add-on to insulin.

3.2 Impact on Body Weight and Blood Pressure

A consistent and beneficial ancillary effect of canagliflozin treatment is the reduction in both body weight and blood pressure. The weight loss is attributed to two primary mechanisms: an initial osmotic diuretic effect leading to fluid loss, followed by sustained caloric loss (estimated at 200-400 kcal/day) due to the excretion of glucose in the urine. Clinical trials have demonstrated weight loss ranging from 2.4 to 4.7 kg over 12 weeks.

Similarly, canagliflozin is associated with modest but consistent reductions in both systolic and diastolic blood pressure (e.g., a reduction of 6/2 mmHg). This effect is largely attributed to the mild, chronic osmotic diuresis caused by glucosuria, which leads to a reduction in intravascular volume. This blood pressure-lowering effect provides an additional advantage, particularly given the high prevalence of hypertension among individuals with T2DM, and contributes to the overall reduction in cardiovascular risk.

3.3 Efficacy in Special Populations

The efficacy and safety of canagliflozin have been evaluated in several specific patient populations.

• Elderly: A clinical trial specifically conducted in adults aged 55 to 80 years confirmed that canagliflozin was both safe and effective for improving glycemic control in this population when diet and exercise alone were insufficient.
• Renal Impairment: Canagliflozin's glucose-lowering efficacy is dependent on renal function, as its mechanism requires glomerular filtration. While its antihyperglycemic effect is attenuated as the estimated glomerular filtration rate (eGFR) declines, studies have shown that it retains moderate efficacy even in patients with moderately impaired renal function (eGFR in the range of 30 to 50 mL/min/1.73 m2). A dedicated clinical trial (NCT01064414) was designed to formally evaluate the efficacy and safety of canagliflozin in patients with T2DM and moderate renal impairment, providing crucial data for this high-risk group.
• Pediatrics: Canagliflozin is approved by the FDA for use in pediatric patients aged 10 years and older with T2DM. The basis for this approval was supported by pharmacokinetic, pharmacodynamic, and safety data from a Phase 1 clinical trial (NCT02000700) that evaluated the drug in older children and adolescents.

4.0 Cardiovascular Protection: The CANVAS Program

The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program was a landmark research initiative that fundamentally reshaped the understanding of canagliflozin, elevating its role from a glucose-lowering agent to a therapy with proven cardiovascular benefits.

Table 2: Summary of Primary and Key Secondary Outcomes from the CANVAS Program

Outcome	Canagliflozin Group (Events/1000 patient-years)	Placebo Group (Events/1000 patient-years)	Hazard Ratio (95% CI)	Source(s)
Primary Composite (MACE: CV Death, Nonfatal MI, Nonfatal Stroke)	26.9	31.5	0.86 (0.75-0.97)*
Hospitalization for Heart Failure	Not Reported	Not Reported	0.67 (0.52-0.87)
Progression of Albuminuria	Not Reported	Not Reported	0.73 (0.67-0.79)
Lower Limb Amputation	6.3	3.4	1.97 (1.41-2.75)
*The hazard ratio for the primary outcome is widely cited from the primary publication in the New England Journal of Medicine and is consistent with the reported event rates.

4.1 Trial Design and Patient Population

The CANVAS Program was a pre-specified integrated analysis of two large, randomized, double-blind, placebo-controlled trials: CANVAS (NCT01032629) and CANVAS-R (NCT01989754). Together, these trials enrolled 10,142 participants with T2DM who were at high risk for cardiovascular events. The mean age of participants was 63.3 years, the mean duration of diabetes was 13.5 years, and a significant majority (65.6%) had a history of established cardiovascular disease at baseline. Participants were randomized to receive canagliflozin (100 mg or 300 mg daily) or placebo, in addition to standard of care, and were followed for a mean of 188.2 weeks.

4.2 Primary and Secondary Cardiovascular Outcomes

The primary outcome of the CANVAS Program was a composite of death from cardiovascular causes, nonfatal myocardial infarction (MI), or nonfatal stroke, collectively known as major adverse cardiovascular events (MACE). The results demonstrated that treatment with canagliflozin led to a statistically significant 14% reduction in the risk of the primary MACE outcome compared to placebo, with event rates of 26.9 versus 31.5 per 1000 patient-years, respectively. This finding was crucial, as it was the first time canagliflozin was proven to provide cardiovascular protection, not just glycemic control.

4.3 Insights into Heart Failure and Renal Outcomes

Beyond the primary MACE endpoint, the CANVAS Program provided important insights into other cardiorenal outcomes. Treatment with canagliflozin was associated with a significant 33% reduction in the risk of hospitalization for heart failure (HHF). This benefit was particularly pronounced in the subgroup of patients who had a history of heart failure at baseline, where the risk reduction was 39% (HR 0.61), compared to a 13% reduction (HR 0.87) in those without a history of heart failure.

The trials also suggested a renal benefit, showing that canagliflozin significantly slowed the progression of albuminuria, a key marker of diabetic kidney disease, with a hazard ratio of 0.73.

4.4 Synthesis and Clinical Implications

The CANVAS Program was pivotal in establishing the cardiovascular benefits of canagliflozin, leading to an expanded FDA indication for the reduction of MACE in adults with T2DM and established cardiovascular disease. However, the trial also produced a complex and challenging finding: the simultaneous discovery of a major benefit and a significant, unexpected risk.

The safety analysis of the CANVAS Program revealed a nearly twofold increased risk of lower limb amputation, primarily at the level of the toe or metatarsal, in patients treated with canagliflozin compared to placebo (HR 1.97). This finding prompted an FDA investigation and the addition of a Boxed Warning—the agency's most stringent warning—to the drug's label in 2017. This created a substantial clinical dilemma for healthcare providers, who had to weigh the proven population-level benefit of MACE reduction against a serious potential risk for individual patients. This dual finding spurred intense research into the potential mechanisms behind the amputation risk and highlighted the critical importance of careful patient selection and proactive risk mitigation strategies, such as routine preventative foot care. This complex risk-benefit profile shaped the clinical perception and use of canagliflozin in the years immediately following the trial's publication.

5.0 Renal Protection: The CREDENCE Trial

Following the suggestive renal benefits observed in the CANVAS Program, the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial was designed to definitively assess the renoprotective effects of canagliflozin. Its results were practice-changing, establishing a new standard of care for patients with diabetic kidney disease.

Table 3: Summary of Primary and Key Secondary Outcomes from the CREDENCE Trial

Outcome	Canagliflozin Group (Events/1000 patient-years)	Placebo Group (Events/1000 patient-years)	Hazard Ratio (95% CI)	Source(s)
Primary Composite (ESKD, Doubling of Serum Creatinine, Renal or CV Death)	43.2	61.2	0.70 (0.59-0.82)
Renal-Specific Composite (ESKD, Doubling of Creatinine, Renal Death)	Not Reported	Not Reported	0.66 (0.53-0.81)
End-Stage Kidney Disease (ESKD)	Not Reported	Not Reported	0.68 (0.54-0.86)
CV Death, MI, or Stroke (MACE)	Not Reported	Not Reported	0.80 (0.67-0.95)
Hospitalization for Heart Failure	Not Reported	Not Reported	0.61 (0.47-0.80)

5.1 Trial Design and Patient Population

The CREDENCE trial (NCT02065791) was a large-scale, randomized, double-blind, placebo-controlled study specifically designed to evaluate the effects of canagliflozin on renal and cardiovascular outcomes. The trial enrolled 4,401 participants with T2DM and established chronic kidney disease, defined as an

eGFR of 30 to <90 mL/min/1.73 m2 and significant albuminuria (urinary albumin-to-creatinine ratio >300 mg/g). All participants were receiving a stable background therapy of a renin-angiotensin system (RAS) inhibitor, which was the standard of care.

In a testament to the drug's profound efficacy, the trial was stopped prematurely by the independent data and safety monitoring committee after a planned interim analysis revealed a clear benefit. The median follow-up at the time of termination was 2.62 years.

5.2 Primary and Secondary Renal and Cardiovascular Outcomes

The primary outcome of the CREDENCE trial was a composite of end-stage kidney disease (ESKD, defined as the need for dialysis or kidney transplantation, or a sustained eGFR <15), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Treatment with canagliflozin 100 mg once daily resulted in a 30% reduction in the relative risk of the primary composite outcome compared with placebo (HR 0.70).

The benefits were consistent and robust across multiple key endpoints. The risk of the renal-specific composite outcome (ESKD, doubling of creatinine, or renal death) was reduced by 34% (HR 0.66), and the risk of ESKD alone was reduced by 32% (HR 0.68). In addition to these powerful renoprotective effects, canagliflozin also demonstrated significant cardiovascular benefits in this high-risk population, reducing the risk of the MACE composite by 20% (HR 0.80) and the risk of hospitalization for heart failure by 39% (HR 0.61).

5.3 Establishing a New Standard of Care in Diabetic Nephropathy

The results of the CREDENCE trial were transformative. By demonstrating substantial renal and cardiovascular benefits on top of the existing standard of care (RAS blockade), canagliflozin was established as a new cornerstone therapy for the management of diabetic nephropathy. The benefits were observed across both primary and secondary cardiovascular prevention subgroups, indicating a broad applicability within this patient population. These findings led to a further expansion of canagliflozin's FDA-approved indications to include reducing the risk of ESKD, doubling of serum creatinine, CV death, and hospitalization for heart failure in adults with T2DM and diabetic nephropathy with albuminuria.

5.4 Synthesis and Clinical Implications

The CREDENCE trial was instrumental not only in confirming the renal benefits of canagliflozin but also in resolving the major safety concern that arose from the CANVAS Program. Critically, the CREDENCE trial did not find a statistically significant increase in the risk of lower limb amputation or bone fracture. This finding was pivotal in rehabilitating the overall safety profile of the drug.

This difference in safety outcomes between the two major trial programs may be attributable to several factors. The CREDENCE trial protocol, designed with knowledge of the CANVAS findings, was amended to mandate that investigators perform foot examinations at each visit and temporarily withhold the study drug in patients with active foot ulcers or infections that could predispose them to amputation. This suggests that the amputation risk, while real, may be mitigated through proactive clinical monitoring and patient education on preventative foot care.

The combination of CREDENCE's powerful efficacy data and its reassuring safety profile provided the FDA with the necessary evidence to re-evaluate the drug's risk-benefit balance. In August 2020, the agency concluded that the well-established cardiorenal benefits of canagliflozin significantly outweighed the risks, and the Boxed Warning regarding amputation risk was removed from the prescribing information. This decision marked the completion of a full and complex arc in the drug's regulatory and clinical assessment, solidifying its role as a key therapeutic agent.

6.0 Emerging Applications and Future Directions

The compelling evidence of cardiorenal protection has spurred research into the use of canagliflozin and other SGLT2 inhibitors beyond their original indication for T2DM, particularly in the management of heart failure and non-diabetic kidney disease.

6.1 Heart Failure Management (CHIEF-HF Trial)

The Canagliflozin: Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) trial (NCT04252287) was a pioneering study that employed a fully remote, decentralized design to evaluate the effect of canagliflozin on patient-reported outcomes in individuals with heart failure. The trial randomized 448 participants with a history of heart failure to receive either canagliflozin 100 mg daily or placebo.

The primary endpoint was the change in the Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) at 12 weeks. The results showed that canagliflozin led to a statistically significant and clinically meaningful improvement in heart failure symptoms compared to placebo, with a mean difference of 4.3 points on the KCCQ-TSS. Notably, this symptomatic benefit was evident as early as two weeks after initiating treatment and was sustained throughout the 12-week study period.

The findings from CHIEF-HF are significant for two key reasons. First, the benefits were consistent across the spectrum of heart failure, including in patients with both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). Second, and most importantly, the symptomatic improvement was observed in patients

with and without T2DM, with 28% of the trial population having DM2. This provides strong evidence that the beneficial effects of SGLT2 inhibitors in heart failure are independent of their glucose-lowering mechanism. These results, alongside data from other SGLT2 inhibitor trials in heart failure, are helping to reposition the entire class as a foundational therapy for heart failure, regardless of a patient's diabetes status.

6.2 Use in Patients Without Diabetes

The positive outcomes in non-diabetic subgroups of heart failure trials have fueled broader investigation into the use of SGLT2 inhibitors for cardiorenal protection in patients without diabetes. A meta-analysis of eight randomized controlled trials confirmed that in patients without diabetes, SGLT2 inhibitors significantly reduce the composite risk of cardiovascular death and heart failure hospitalizations.

While the CREDENCE trial focused on diabetic nephropathy, subsequent trials with other SGLT2 inhibitors, such as DAPA-CKD (dapagliflozin) and EMPA-KIDNEY (empagliflozin), have demonstrated clear renal benefits in patients with chronic kidney disease (CKD) both with and without T2DM. This suggests a class-wide nephroprotective effect that is likely applicable to canagliflozin as well, driven by mechanisms beyond glycemic control, such as reducing intraglomerular pressure, inflammation, and fibrosis.

6.3 Potential in Obesity and Other Metabolic Conditions

Given its mechanism of inducing caloric loss, canagliflozin has been explored as a potential therapy for obesity. It has been evaluated in Phase II clinical trials for this indication. A small clinical trial (NCT02912455) also investigated its use in patients with recurrent T2DM following bariatric surgery, a population where weight management is critical. While not sufficient for significant weight loss as a monotherapy, its potential may lie in combination with appetite-suppressing agents, such as GLP-1 receptor agonists, where adjuvant therapy has shown enhanced weight reduction.

Canagliflozin has also been studied in patients with Type 1 Diabetes Mellitus (T1DM). However, it is not an approved indication due to a significantly increased risk of diabetic ketoacidosis in this population.

7.0 Comprehensive Safety and Tolerability Profile

The clinical use of canagliflozin requires a thorough understanding of its safety profile, which includes a range of common, manageable side effects as well as rare but serious adverse events that necessitate careful patient selection and monitoring.

7.1 Common Adverse Events

The most frequently reported adverse events associated with canagliflozin are a direct consequence of its mechanism of inducing glucosuria.

• Genital Mycotic Infections: This is the most common side effect. The increased glucose concentration in the urine creates a favorable environment for the growth of yeast. This leads to a higher incidence of vulvovaginal candidiasis in females and balanitis or balanoposthitis in males.
• Urinary Tract Infections (UTIs): An increased incidence of UTIs has been reported in clinical trials. While most cases are uncomplicated, rare but serious cases of urosepsis and pyelonephritis requiring hospitalization have been documented, necessitating prompt evaluation and treatment of any UTI symptoms.
• Increased Urination and Thirst: The osmotic diuresis caused by glucosuria leads to increased urinary frequency (polyuria), including at night (nocturia), and can lead to increased thirst (polydipsia) and dry mouth.

7.2 Serious Adverse Events and Risk Management

7.2.1 Lower Limb Amputation: A Detailed Risk Analysis

The risk of lower limb amputation is the most notable and historically significant safety concern associated with canagliflozin. An integrated analysis of the CANVAS Program revealed a nearly twofold increased risk of amputation (HR 1.97), primarily involving the toe and midfoot, in patients treated with canagliflozin compared to placebo. This finding led the FDA to issue a Boxed Warning in 2017. However, the subsequent CREDENCE trial, which included enhanced foot care monitoring in its protocol, did not show a statistically significant increase in amputation risk. This later finding, combined with the overwhelming evidence of cardiorenal benefit, led the FDA to remove the Boxed Warning in 2020. The risk, however, remains listed in the "Warnings and Precautions" section of the drug's label. Risk factors that may predispose patients to this complication include a prior history of amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers. Routine preventative foot care and monitoring for new pain, tenderness, sores, or infections in the lower limbs are critical for risk mitigation.

7.2.2 Diabetic Ketoacidosis (DKA), including Euglycemic DKA

Canagliflozin, like other SGLT2 inhibitors, is associated with a risk of serious, life-threatening diabetic ketoacidosis. A particularly challenging aspect of this risk is that DKA can occur with only modestly elevated or even normal blood glucose levels (less than 250 mg/dL), a condition known as euglycemic DKA. The risk is highest in patients with T1DM (for whom the drug is not recommended), but also increases during periods of acute illness, surgery, prolonged fasting, or adherence to a ketogenic diet. Patients should be counseled on the signs and symptoms of DKA (nausea, vomiting, abdominal pain, fatigue, difficulty breathing) and advised to seek immediate medical attention if they occur. It is recommended to withhold canagliflozin therapy for at least 3 days prior to scheduled surgery.

7.2.3 Acute Kidney Injury and Volume Depletion

The osmotic diuretic effect of canagliflozin can lead to intravascular volume contraction, which may cause symptomatic hypotension (dizziness, lightheadedness, fainting) or, in some cases, acute kidney injury (AKI). The risk of these adverse events is elevated in elderly patients, individuals with pre-existing renal impairment, and those taking loop diuretics. Assessment and correction of volume status are recommended before initiating therapy, along with ongoing monitoring.

7.2.4 Bone Fractures and Mineral Density

An increased risk of bone fractures, particularly in the upper extremities and distal lower extremities, has been observed in patients taking canagliflozin, with some fractures occurring as early as 12 weeks after starting treatment. Studies have also linked canagliflozin to decreases in bone mineral density at the hip and lower spine. A dedicated clinical trial (NCT02404870) was initiated to investigate the drug's acute effects on hormonal regulators of bone and mineral metabolism, such as fibroblast growth factor 23 (FGF23) and parathyroid hormone (PTH). Clinicians should consider factors that contribute to fracture risk when prescribing canagliflozin.

7.2.5 Fournier's Gangrene and Other Rare Events

Fournier's gangrene, a rare but life-threatening necrotizing fasciitis of the perineum, has been reported in post-marketing surveillance for the SGLT2 inhibitor class, affecting both males and females. Patients presenting with pain, tenderness, erythema, or swelling in the genital or perineal area, especially if accompanied by fever or malaise, require immediate medical assessment. Rare cases of serious hypersensitivity reactions, including anaphylaxis and angioedema, have also been reported.

7.3 Contraindications and Precautions

• Contraindications: Canagliflozin is contraindicated in patients with a history of a serious hypersensitivity reaction (e.g., anaphylaxis, angioedema) to the drug and in patients on dialysis.
• Precautions: Canagliflozin is not recommended for the treatment of T1DM or DKA. It should be used with caution in patients with known risk factors for amputation, volume depletion, DKA, and bone fractures.

8.0 Comparative Analysis within the SGLT2 Inhibitor Class

With several SGLT2 inhibitors available, clinicians must often choose among them. While many of the major cardiorenal benefits appear to be a class effect, comparative effectiveness studies and real-world data have revealed subtle but potentially important differences between canagliflozin, dapagliflozin, and empagliflozin.

Table 4: Comparative Overview of Canagliflozin, Dapagliflozin, and Empagliflozin

Parameter	Canagliflozin	Dapagliflozin	Empagliflozin	Source(s)
HbA1c​ Reduction	Intermediate	Lower	Higher
Systolic BP Reduction	Higher	Lower	Intermediate
Weight/BMI Change	No significant difference	No significant difference	No significant difference
Risk of HF Hospitalization (vs. Empagliflozin)	Comparable	Higher (esp. at 5 mg dose)	Reference
Risk of Genital Infections (vs. Empagliflozin)	Lower	Lower	Reference
Risk of Severe UTIs (vs. Empagliflozin)	Higher	Comparable	Reference
Risk of DKA (vs. Empagliflozin)	Comparable	Lower	Reference

8.1 Efficacy Compared to Dapagliflozin and Empagliflozin

A large comparative effectiveness study using target trial emulation concluded that canagliflozin, dapagliflozin, and empagliflozin demonstrate comparable cardiovascular effectiveness at clinically recommended doses. However, the study did note that low-dose (5 mg) dapagliflozin showed reduced effectiveness in preventing heart failure hospitalization compared to empagliflozin.

A separate real-world observational cohort study from the UK involving over 21,000 patients found small but statistically significant differences in secondary efficacy outcomes. Empagliflozin was associated with the largest mean reduction in HbA1c​ (−10.6 mmol/mol), followed by canagliflozin (−9.8 mmol/mol) and dapagliflozin (−9.1 mmol/mol). Conversely, canagliflozin was associated with a statistically larger reduction in systolic blood pressure compared to dapagliflozin (

−1.6 mmHg vs. −0.6 mmHg). No significant differences were observed among the three agents in their effect on weight or BMI reduction.

8.2 Differentiated Safety Profiles

The same comparative effectiveness study that found similar cardiovascular efficacy also highlighted variances in the safety profiles of the individual agents. Compared to empagliflozin, canagliflozin was associated with a lower risk of genital infections but a higher risk of severe UTIs. Dapagliflozin was associated with a lower risk of both genital infections and diabetic ketoacidosis compared to empagliflozin.

These nuanced differences, while not derived from head-to-head randomized controlled trials, may help guide individualized therapy. For instance, a patient with refractory hypertension might derive greater benefit from the more pronounced blood pressure-lowering effect of canagliflozin. In contrast, a patient with a history of recurrent severe UTIs might be a better candidate for empagliflozin or dapagliflozin. Similarly, for a patient with multiple risk factors for DKA, dapagliflozin might be preferred. These findings underscore that while the major cardiorenal benefits are likely a class effect, the choice of a specific SGLT2 inhibitor can be tailored to a patient's unique clinical profile and risk factors.

9.0 Clinical Practice Guidance

The safe and effective use of canagliflozin requires adherence to specific guidelines for dosing, administration, patient selection, and monitoring.

9.1 Dosing and Administration

Canagliflozin is administered orally once daily and should be taken before the first meal of the day to optimize its effect on postprandial glucose.

Table 5: Dosing Recommendations in Adults and Pediatric Patients (≥10 years)

Indication	Starting Dose	Titration / Maximum Dose	Source(s)
Glycemic Control in T2DM	100 mg once daily	May be increased to 300 mg once daily for additional glycemic control if tolerated and eGFR ≥60 mL/min/1.73 m2.
CV Risk Reduction (Adults)	100 mg once daily	The recommended and maximum dose for this indication is 100 mg once daily.
Diabetic Nephropathy (Adults)	100 mg once daily	The recommended and maximum dose for this indication is 100 mg once daily.

Dosage must be adjusted based on renal function and in the presence of certain interacting medications.

Table 6: Dosage Adjustments for Renal Impairment and Drug Interactions

Patient Group	Recommended Dosage	Source(s)
eGFR ≥60 mL/min/1.73 m2	No adjustment necessary. Can be titrated to 300 mg for glycemic control.
eGFR 30 to <60 mL/min/1.73 m2	Maximum recommended dose is 100 mg once daily.
eGFR <30 mL/min/1.73 m2	Initiation is not recommended. Adult patients already taking 100 mg for diabetic nephropathy with albuminuria >300 mg/day may continue therapy to reduce renal/CV risk.
Patients on Dialysis	Contraindicated.
Concomitant Use with UGT Inducers (e.g., rifampin)	If eGFR ≥60: Increase dose to 200 mg or 300 mg daily if 100 mg is tolerated. If eGFR <60: Increase to a maximum of 200 mg daily if 100 mg is tolerated.

9.2 Patient Selection and Monitoring

Before initiating canagliflozin, clinicians should perform a thorough assessment that includes:

• Renal Function: An eGFR should be obtained at baseline and monitored periodically thereafter.
• Volume Status: Assess for and correct any volume depletion, especially in elderly patients, those with low blood pressure, or those on loop diuretics.
• Risk Factor Assessment: Evaluate the patient's risk for amputation (history of peripheral artery disease, neuropathy, foot ulcers) and DKA (pancreatic insufficiency, history of DKA).

During therapy, patients should be monitored for signs and symptoms of volume depletion, genital mycotic infections, UTIs, and any new pain, tenderness, sores, or ulcers on their legs or feet. It is important to note that routine urine glucose tests are not a reliable method for monitoring glycemic control in patients taking SGLT2 inhibitors, as the drug's mechanism will invariably lead to a positive result. Glycemic control should be monitored using

HbA1c​.

9.3 Significant Drug-Drug Interactions

• UGT Enzyme Inducers: Potent inducers of UGT enzymes (e.g., rifampin, phenytoin, phenobarbital, ritonavir) can significantly decrease canagliflozin exposure and efficacy. An increase in canagliflozin dosage is required in these situations, as outlined in Table 6.
• Digoxin: Canagliflozin can increase the plasma concentration of digoxin. When co-administered, digoxin levels should be monitored, and the digoxin dose may need to be adjusted.
• Insulin and Insulin Secretagogues (e.g., sulfonylureas): The concomitant use of canagliflozin with these agents increases the risk of hypoglycemia. A reduction in the dose of the insulin or insulin secretagogue may be necessary to mitigate this risk.
• Lithium: Co-administration of SGLT2 inhibitors with lithium may decrease serum lithium concentrations. More frequent monitoring of serum lithium is recommended during canagliflozin initiation and dosage changes.

10.0 Conclusion: Synthesis and Overall Perspective

Canagliflozin stands as a foundational agent in the SGLT2 inhibitor class and a pivotal therapy in the modern management of cardiorenal-metabolic disease. Its journey from a novel glucose-lowering drug to a multifaceted protective agent illustrates a significant evolution in therapeutic understanding, driven by rigorous, large-scale clinical evidence.

10.1 Summary of Canagliflozin's Risk-Benefit Profile

The therapeutic value of canagliflozin is defined by a compelling risk-benefit profile. The benefits are profound and well-established, including robust improvements in glycemic control, modest reductions in body weight and blood pressure, and, most importantly, proven efficacy in reducing the risk of major adverse cardiovascular events and slowing the progression of diabetic kidney disease. Emerging data further support its role in improving symptoms of heart failure, expanding its potential utility.

These substantial benefits must be carefully weighed against a distinct set of risks. The most common adverse events—genital mycotic infections and UTIs—are generally manageable but require patient education and vigilance. More serious risks, including diabetic ketoacidosis, volume depletion, and bone fractures, necessitate careful patient selection and monitoring. The historically important risk of lower limb amputation, identified in the CANVAS Program, has been contextualized by subsequent data from the CREDENCE trial, suggesting the risk can be mitigated with appropriate preventative care. The FDA's ultimate removal of the Boxed Warning reflects a consensus that for appropriately selected and monitored patients, the cardiorenal benefits of canagliflozin are overwhelming.

10.2 The Trajectory of Canagliflozin in Modern Medicine

The story of canagliflozin is a powerful case study in contemporary drug development and lifecycle management. It demonstrates how post-marketing surveillance and large-scale outcome trials, initially mandated to ensure safety, can uncover unexpected and practice-changing benefits. This process has fundamentally redefined the therapeutic value of canagliflozin and its entire class, transforming them from third-line diabetes agents into first-line therapies for patients with T2DM and compelling comorbidities like atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease. This evolution has forced a paradigm shift in clinical guidelines, moving away from isolated disease management toward an integrated approach to treating a spectrum of interrelated chronic conditions. Canagliflozin's journey from its launch as the first SGLT2 inhibitor in the US to its current status as a key agent for cardiorenal protection marks it as a truly significant contribution to modern medicine.

Works cited

1. Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus - PMC - PubMed Central, accessed July 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3978932/
2. SGLT2 inhibitor - Wikipedia, accessed July 26, 2025, https://en.wikipedia.org/wiki/SGLT2_inhibitor
3. Canagliflozin | CAS#842133-18-0 | 928672-86-0 | SGLT2 inhibitor | MedKoo Biosciences, accessed July 26, 2025, https://www.medkoo.com/products/6448
4. Canagliflozin - StatPearls - NCBI Bookshelf, accessed July 26, 2025, https://www.ncbi.nlm.nih.gov/books/NBK603733/
5. SGLT2 Inhibitors: A Review of Canagliflozin - U.S. Pharmacist, accessed July 26, 2025, https://www.uspharmacist.com/article/sglt2-inhibitors-a-review-of-canagliflozin
6. Canagliflozin: MedlinePlus Drug Information, accessed July 26, 2025, https://medlineplus.gov/druginfo/meds/a613033.html
7. Invokana (Canagliflozin): First-in-Class SGLT2 Inhibitor Approved for the Treatment of Type 2 Diabetes - American Health & Drug Benefits, accessed July 26, 2025, https://www.ahdbonline.com/web-exclusives/1575-invokana-canagliflozin-first-in-class-sglt2-inhibitor-approved-for-the-treatment-of-type-2-diabetes
8. Canagliflozin - Johnson & Johnson/Mitsubishi Tanabe Pharma Corporation - AdisInsight, accessed July 26, 2025, https://adisinsight.springer.com/drugs/800026535
9. Canagliflozin: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed July 26, 2025, https://www.medcentral.com/drugs/monograph/163872-313046/canagliflozin-oral
10. This label may not be the latest approved by FDA. For current ..., accessed July 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204042s034lbl.pdf
11. CANagliflozin cardioVascular Assessment Study (CANVAS) - ClinicalTrials.gov, accessed July 26, 2025, https://clinicaltrials.gov/study/NCT01032629
12. Canagliflozin and Cardiovascular and Renal Events in Type 2 ..., accessed July 26, 2025, https://www.acc.org/-/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Tools-and-Practice-Support/Quality-Programs/Diabetes-Roundtable-2017/SupplementalReading/Canagliflozin-and-Cardiovascular-and-Renal-Events-in-Type-2-Diabetes-CA.pdf
13. Canagliflozin Cardiovascular Assessment Study - American College of Cardiology, accessed July 26, 2025, https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2017/06/12/16/25/CANVAS
14. The CREDENCE trial: The effect of canagliflozin on renal function ..., accessed July 26, 2025, https://www.2minutemedicine.com/the-credence-trial-the-effect-of-canagliflozin-on-renal-function/
15. CREDENCE - Primary renal outcome benefit demonstrated with Canagliflozin 100mg . Published in NEJM April 14th 2019, accessed July 26, 2025, https://abcd.care/announcement/credence-primary-renal-outcome-benefit-demonstrated-canagliflozin-100mg-published-nejm
16. Canagliflozin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 26, 2025, https://go.drugbank.com/drugs/DB08907
17. INVOKANA® (canagliflozin) | Official Consumer Website, accessed July 26, 2025, https://www.invokana.com/
18. Canagliflozin - brand name list from Drugs.com, accessed July 26, 2025, https://www.drugs.com/ingredient/canagliflozin.html
19. Canagliflozin - Wikipedia, accessed July 26, 2025, https://en.wikipedia.org/wiki/Canagliflozin
20. Canagliflozin | CAS 842133-18-0 | SCBT - Santa Cruz Biotechnology, accessed July 26, 2025, https://www.scbt.com/p/canagliflozin-842133-18-0
21. Canagliflozin | 842133-18-0 | MC58356 - Biosynth, accessed July 26, 2025, https://www.biosynth.com/p/MC58356/842133-18-0-canagliflozin
22. 3D structure for Canagliflozin (DB08907) | DrugBank Online, accessed July 26, 2025, https://go.drugbank.com/structures/small_molecule_drugs/DB08907
23. Canagliflozin (JNJ-24831754, TA-7284, CAS Number: 842133-18-0) | Cayman Chemical, accessed July 26, 2025, https://www.caymanchem.com/product/11575/canagliflozin
24. Invokana (Canagliflozin Tablets): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 26, 2025, https://www.rxlist.com/invokana-drug.htm
25. INVOKANA (canagliflozin) tablets - accessdata.fda.gov, accessed July 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204042s026lbl.pdf
26. Canagliflozin (JNJ 28431754) | SGLT2 Inhibitor - MedchemExpress.com, accessed July 26, 2025, https://www.medchemexpress.com/Canagliflozin.html
27. Canagliflozin (oral route) - Side effects & dosage - Mayo Clinic, accessed July 26, 2025, https://www.mayoclinic.org/drugs-supplements/canagliflozin-oral-route/description/drg-20060957
28. 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INVOKANA safely and e - Janssen, accessed July 26, 2025, https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVOKANA-pi.pdf
29. Invokana (canagliflozin) dosing, indications, interactions, adverse effects, and more, accessed July 26, 2025, https://reference.medscape.com/drug/invokana-canagliflozin-999811
30. A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment - The YODA Project, accessed July 26, 2025, https://yoda.yale.edu/clinical-trial/nct01064414-a-randomized-double-blind-placebo-controlled-3-arm-parallel-group-26-week-multicenter-study-with-a-26-week-extension-to-evaluate-the-efficacy-safety-and-tolerability-of-canaglifl/
31. An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment | ClinicalTrials.gov, accessed July 26, 2025, https://clinicaltrials.gov/study/NCT01064414
32. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights ..., accessed July 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/204042s043lbl.pdf
33. Canagliflozin Completed Phase 1 Trials for Type 2 Diabetes Mellitus Treatment - DrugBank, accessed July 26, 2025, https://go.drugbank.com/drugs/DB08907/clinical_trials?conditions=DBCOND0029752&phase=1&purpose=treatment&status=completed
34. INVOKANA® (canagliflozin) Significantly Reduces the Risk of Heart Failure- Related Outcomes in Type 2 Diabetes Patients at Risk for or With a History of Cardiovascular Disease, accessed July 26, 2025, https://www.jnj.com/media-center/press-releases/invokana-canagliflozin-significantly-reduces-the-risk-of-heart-failure-related-outcomes-in-type-2-diabetes-patients-at-risk-for-or-with-a-history-of-cardiovascular-disease
35. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes - PubMed, accessed July 26, 2025, https://pubmed.ncbi.nlm.nih.gov/28605608/
36. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program - PMC - PubMed Central, accessed July 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6075881/
37. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials - PubMed, accessed July 26, 2025, https://pubmed.ncbi.nlm.nih.gov/29937267/
38. FDA Drug Safety Communication: Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate, accessed July 26, 2025, https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-interim-clinical-trial-results-find-increased-risk-leg-and-foot
39. Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE) - ClinicalTrials.gov, accessed July 26, 2025, https://clinicaltrials.gov/study/NCT02065791
40. Clinical Credence — SGLT2 Inhibitors, Diabetes, and Chronic Kidney Disease, accessed July 26, 2025, http://www.endo-smc.umin.jp/x/r/nejm_Credence_editorial.pdf
41. Study Results | Evaluation of the Effects of Canagliflozin on Renal ..., accessed July 26, 2025, https://clinicaltrials.gov/study/NCT02065791?tab=results
42. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial - PMC, accessed July 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6727954/
43. The SGLT2i Crescendo with CREDENCE - NephJC, accessed July 26, 2025, http://www.nephjc.com/news/credence
44. FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) | FDA, accessed July 26, 2025, https://www.fda.gov/drugs/drug-safety-and-availability/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin
45. Heart failure symptoms improved with a type 2 diabetes medicine in fully remote trial, accessed July 26, 2025, https://newsroom.heart.org/news/heart-failure-symptoms-improved-with-a-type-2-diabetes-medicine-in-fully-remote-trial
46. CHIEF-HF: Fully Remote Clinical Trial Shows Canagliflozin Improved HF Symptoms in Patients With/Without Diabetes - American College of Cardiology, accessed July 26, 2025, https://www.acc.org/Latest-in-Cardiology/Articles/2021/11/08/12/02/sun-415pm-chief-hf-aha-2021
47. Canagliflozin Impact on Health Status, Quality of Life, and Functional ..., accessed July 26, 2025, https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2021/11/12/00/23/CHIEF-HF
48. CHIEF-HF: Canagliflozin improves health status in heart failure - Medical Conferences, accessed July 26, 2025, https://conferences.medicom-publishers.com/specialisation/cardiology/aha-2021/chief-hf-canagliflozin-improves-health-status-in-heart-failure/
49. Sodium Glucose Cotransporter-2 Inhibitors in Non-Diabetic Kidney Disease: Evidence in Experimental Models - MDPI, accessed July 26, 2025, https://www.mdpi.com/1424-8247/17/3/362
50. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials - American Heart Association Journals, accessed July 26, 2025, https://www.ahajournals.org/doi/10.1161/JAHA.120.019463
51. SGLT2i use in non-diabetics - eCommons@AKU, accessed July 26, 2025, https://ecommons.aku.edu/cgi/viewcontent.cgi?article=1099&context=pakistan_fhs_mc_med_diabet_endocrinol_metab
52. SGLT2 inhibitors and finerenone in non-diabetic CKD: a step into the (near) future? | Clinical Kidney Journal | Oxford Academic, accessed July 26, 2025, https://academic.oup.com/ckj/article/17/1/sfad272/7328959
53. CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes | ClinicalTrials.gov, accessed July 26, 2025, https://clinicaltrials.gov/study/NCT02912455
54. Type 1 Diabetes Mellitus (T1DM) Completed Phase Trials for Canagliflozin (DB08907), accessed July 26, 2025, https://go.drugbank.com/indications/DBCOND0077686/clinical_trials/DB08907?phase=&status=completed
55. Janssen Expands Body of Evidence for INVOKANA® (canagliflozin) with 18 New Data Presentations at American Diabetes Association's 76th Scientific Sessions®, accessed July 26, 2025, https://www.jnj.com/media-center/press-releases/janssen-expands-body-of-evidence-for-invokana-canagliflozin-with-18-new-data-presentations-at-american-diabetes-associations-76th-scientific-sessions
56. Canagliflozin (Invokana): Uses & Side Effects - Cleveland Clinic, accessed July 26, 2025, https://my.clevelandclinic.org/health/drugs/19205-canagliflozin-tablets
57. FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density, accessed July 26, 2025, https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invokamet
58. Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers | ClinicalTrials.gov, accessed July 26, 2025, https://clinicaltrials.gov/study/NCT02404870
59. View of Real-world cross-comparison of metabolic outcomes with different sodium-glucose co-transporter 2 inhibitors agents in adults with type 2 diabetes: results from the Association of British Clinical Diabetologists audit programme, accessed July 26, 2025, https://www.bjd-abcd.com/index.php/bjd/article/view/1209/1511
60. Real-world cross-comparison of metabolic outcomes with different sodium-glucose co-transporter 2 inhibitors agents in - British Journal of Diabetes, accessed July 26, 2025, https://bjd-abcd.com/index.php/bjd/article/download/1209/1509/11631
61. Do Individual SGLT-2 Inhibitors Differ in Safety, Effectiveness?, accessed July 26, 2025, https://www.uspharmacist.com/article/do-individual-sglt2-inhibitors-differ-in-safety-effectiveness
62. Invokana Dosage Guide: Adjustments and Instructions - GoodRx, accessed July 26, 2025, https://www.goodrx.com/invokana/dosage
63. INVOKANA® (canagliflozin) Official Website HCP, accessed July 26, 2025, https://www.invokanahcp.com/
64. INVOKANA® (canagliflozin) Overview | J&J withMe for Healthcare Professionals, accessed July 26, 2025, https://www.jnjwithme.com/hcp/invokana/